RxDoctor Payments Data

Cary Hirsch, MD

Interventional Cardiology · Suffern, NYNPI 1215965298

Payments from drug & device makers

$12,545in general payments, 2019–2025

Across 266 payments — averaging $47.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$6K
  • Abbott$1K
  • Amgen$1K
  • Boston Scientific$630
  • Medtronic$466
  • Abiomed$453
  • plus $3K from 32 others

What the payments were for

  • Speaking & faculty fees$6,40051%
  • Food & beverage$5,96848%
  • Education$1771%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,545 in reported general payments places this provider in the 50th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$286,322
Medicare patients
751
Services billed
3,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban278$406,653
XareltoRivaroxaban200$200,632
EntrestoSacubitril/Valsartan127$169,416
JardianceEmpagliflozin116$142,591
FarxigaDapagliflozin Propanediol109$141,314
OzempicSemaglutide122$138,958
Repatha SureclickEvolocumab114$119,886
WegovySemaglutide37$52,374
Praluent PenAlirocumab39$35,102
MounjaroTirzepatide19$29,386
Nebivolol Hcl313$24,551
VascepaIcosapent Ethyl28$19,790
Ezetimibe593$16,884
Rosuvastatin Calcium1,026$16,839
Metoprolol Succinate399$7,360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$256$406,653278 claims
Johnson & JohnsonXarelto$333$200,632200 claims
Novo NordiskOzempic, Wegovy$66$191,333159 claims
NovartisEntresto$5,849$169,416127 claims
Boehringer IngelheimJardiance$75$142,591116 claims
AstraZenecaFarxiga$257$141,314109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Suffern

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →